A Study of Renal Microvessel Imaging for Chronic Kidney Disease
Status:
Not yet recruiting
Trial end date:
2028-04-01
Target enrollment:
Participant gender:
Summary
The purpose of this research is to study the efficacy of ultrasound microvessel imaging for
evaluation of Chronic Kidney Disease. Lumason is an ultrasound contrast agent currently
approved by the FDA for use on the heart, liver, and urinary tract. This study will look at
its effectiveness on the kidney.
Phase:
Phase 2
Details
Lead Sponsor:
Mayo Clinic
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)